LLY

749.85

+1.61%↑

JNJ

177.08

-0.6%↓

ABBV

210.45

+0.22%↑

UNH

348.61

+8.84%↑

NVO

54.26

-0.09%↓

LLY

749.85

+1.61%↑

JNJ

177.08

-0.6%↓

ABBV

210.45

+0.22%↑

UNH

348.61

+8.84%↑

NVO

54.26

-0.09%↓

LLY

749.85

+1.61%↑

JNJ

177.08

-0.6%↓

ABBV

210.45

+0.22%↑

UNH

348.61

+8.84%↑

NVO

54.26

-0.09%↓

LLY

749.85

+1.61%↑

JNJ

177.08

-0.6%↓

ABBV

210.45

+0.22%↑

UNH

348.61

+8.84%↑

NVO

54.26

-0.09%↓

LLY

749.85

+1.61%↑

JNJ

177.08

-0.6%↓

ABBV

210.45

+0.22%↑

UNH

348.61

+8.84%↑

NVO

54.26

-0.09%↓

Home・Elenco Azioni・Charles River Laboratories International Inc

Charles River Laboratories International Inc

Chiusa

SettoreSettore sanitario

157.95 -2.39

Acquista Vendi

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

153.91

Massimo

163.42

Metriche Chiave
By Trading Economics
Entrata	27M 53M
Vendite	48M 1B
P/E Media del settore	592.3 35.733
Margine di Profitto	5.105
Dipendenti	18,700
EBITDA	37M 221M

Raccomandazioni
By TipRanks
Raccomandazioni	Acquista
Previsioni per 12 mesi	+6.9% upside

Statistiche di mercato
By TradingEconomics
Capitalizzazione di Mercato	-275M 8B
Apertura precedente	160.34
Chiusura precedente	157.95

Notizie sul Sentiment di mercato

By Acuity

76%

24%

345 / 371 Classifica in Healthcare

Punteggio Tecnico

By Trading Central

Fiducia

Strong Bullish Evidence

117.16 / 144.77 Supporto e resistenza

Charles River Laboratories International Inc Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

9 set 2025, 23:37 UTC

Azioni calde

Stocks to Watch: Oracle, Wearable Devices, GameStop

9 set 2025, 20:41 UTC

Utili

Oracle's Backlog Surges With Major Customer Deals in 1Q

9 set 2025, 20:30 UTC

Utili

GameStop 2Q Sales, Profit Rise

9 set 2025, 23:19 UTC

Discorsi di Mercato

ANZ Adds a Further 50 Bps in FOMC Cuts to Outlook -- Market Talk

9 set 2025, 21:35 UTC

Utili

Oracle Stock Soars on Strong AI Backlog. Earnings Were Good Enough. -- Barrons.com

9 set 2025, 21:32 UTC

Utili

Oracle's Backlog Swells With Big Customer Deals -- Update

9 set 2025, 21:02 UTC

Acquisizioni, Fusioni, Takeovers

DHL Adds to Healthcare Logistics Services With Acquisition -- Update

9 set 2025, 20:50 UTC

Discorsi di Mercato

Basic Materials Roundup: Market Talk

9 set 2025, 20:33 UTC

Utili

These Stocks Moved the Most Today: Apple, UnitedHealth, Nebius, Wolfspeed, Tourmaline Bio, Albemarle, Dell, and More -- Barrons.com

9 set 2025, 20:26 UTC

Utili

Oracle Stock Soars on Strong Backlog. Earnings Were Good Enough. -- Barrons.com

9 set 2025, 20:23 UTC

Utili

Oracle Stock Soars on Strong Backlog. Earnings Were Good Enough. -- Barrons.com

9 set 2025, 20:12 UTC

Utili

Oracle Stock Jumps on Mixed Earnings Report -- Barrons.com

9 set 2025, 20:10 UTC

Utili

Oracle Expects Cloud Infrastructure Rev to Grow 77% to $18 B This Fiscal Yr >ORCL

9 set 2025, 20:10 UTC

Utili

Oracle Expects to Sign-Up Several Additional Multi-B-dollar Customers and RPO Is Likely to Exceed Half-A-Trillion Dollars Over Next Few Mos

9 set 2025, 20:09 UTC

Utili

Synopsys Sees 4Q Adj EPS $2.76-Adj EPS $2.80 >SNPS

9 set 2025, 20:09 UTC

Utili

Synopsys Sees 4Q Loss/Shr 16c-Loss 27c >SNPS

9 set 2025, 20:08 UTC

Utili

Oracle 1Q Short-term Deferred Rev Were $12.1 B >ORCL

9 set 2025, 20:08 UTC

Utili

Oracle 1Q Operating Income Was $4.3 B >ORCL

9 set 2025, 20:08 UTC

Utili

Oracle Expects MultiCloud Rev to Grow Substantially Every Qtr for Several Years >ORCL

9 set 2025, 20:08 UTC

Utili

Synopsys Sees 4Q Rev $2.23B-$2.26B >SNPS

9 set 2025, 20:07 UTC

Utili

Oracle Total Remaining Performance Obligations Up to $455 B >ORCL

9 set 2025, 20:06 UTC

Utili

Oracle 1Q Software Revenue $5.72B >ORCL

9 set 2025, 20:06 UTC

Utili

Synopsys 3Q Adj EPS $3.39 >SNPS

9 set 2025, 20:06 UTC

Utili

Oracle 1Q Cloud Revenue $7.19B >ORCL

9 set 2025, 20:05 UTC

Utili

Oracle 1Q Rev $14.93B >ORCL

9 set 2025, 20:05 UTC

Utili

Oracle 1Q EPS $1.01 >ORCL

9 set 2025, 20:05 UTC

Utili

Synopsys 3Q EPS $1.50 >SNPS

9 set 2025, 20:05 UTC

Utili

Oracle 1Q Services Revenue $1.35B >ORCL

9 set 2025, 20:05 UTC

Utili

Oracle 1Q Adj EPS $1.47 >ORCL

9 set 2025, 20:05 UTC

Utili

Oracle 1Q Hardware Revenue $670M >ORCL

Confronto tra pari

Modifica del prezzo

Charles River Laboratories International Inc Previsione

Obiettivo di Prezzo

By TipRanks

6.9% in crescita

Previsioni per 12 mesi

Media 173.18 USD 6.9%

Alto 195 USD

Basso 151 USD

Basato su 13 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Charles River Laboratories International Inc - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Acquista

13 ratings

Acquista

Mantieni

Vendi

Basato sugli analisti di 13 che hanno fornito valutazioni azionarie a Charles River Laboratories International Inc - Dist negli ultimi 3 mesi.

Punteggio Tecnico

By Trading Central

117.16 / 144.77Supporto e resistenza

Recent bullish events outweigh bearish events.

All events are bearish.

Sentiment

By Acuity

345 / 371 Classifica in Settore sanitario

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

Chi Siamo Charles River Laboratories International Inc

Charles River Laboratories International, Inc. provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing). The RMS segment produces and sells rodents, and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening pre-clinical drug candidates, including research models, genetically engineered models and services, insourcing solutions, and research animal diagnostic services. The DSA segment offers early and in vivo discovery services for the identification and validation of novel targets, chemical compounds, and antibodies through delivery of preclinical drug and therapeutic candidates ready for safety assessment; and safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services. The Manufacturing segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products. This segment also offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies. It also provides contract vivarium operation services to biopharmaceutical clients. The company was founded in 1947 and is headquartered in Wilmington, Massachusetts.